Ignite Creation Date:
2024-05-06 @ 7:46 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06132230
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-11-15
First Post:
2023-11-09
Brief Title:
Potential Value of Immunohistochemical Expression of SOX17 and E-Cadherin in Variable Endometrial Lesions
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
Potential Value of Immunohistochemical Expression of SOX17 and E-Cadherin in Variable Endometrial Lesions
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Endometrial carcinoma EC is the 6th most commonly occurring cancer in women and the 15th most common cancer overall According to facts derived from Globocan for the year 2020The overall incidence was 417367 and 97370 died due to it There were more than 417000 new cases of endometrial cancer in 2020 EC incidence is predicted to continue to rise in the coming decades in particular among low and middle-income countries
SOX17 protein SRY-box 17 is a member of the SRY-related HMG-box SOX family of transcription factors that controls the first step of gene expression and regulates cellular growth and differentiation in the endoderm during hematopoiesis and in the cardiovascular system E-Cadherin is a calcium-dependent cell adhesion protein predicted molecular weight of 97 kDa that plays a vital role in cell migration and proliferation The E-cadherin epithelial cell adhesion protein is a tumor suppressor that has an important role in tumor metastasis The loss of expression of E-Cadherin during the epithelial mesenchymal transition EMT is often thought to promote metastasis by allowing the dissociation and invasion of cancer cells
The aim of this study is
1 To evaluate accuracy of SOX17 expression in neoplastic and hyperplastic endometrial lesions
2 To correlate SOX17 expression with some clinical and pathological parameters of endometrial carcinoma
3 To evaluate E-Cadhrin expression and its relation to SOX17 in neoplastic and hyperplastic lesions
SOX17 protein SRY-box 17 is a member of the SRY-related HMG-box SOX family of transcription factors that controls the first step of gene expression and regulates cellular growth and differentiation in the endoderm during hematopoiesis and in the cardiovascular system E-Cadherin is a calcium-dependent cell adhesion protein predicted molecular weight of 97 kDa that plays a vital role in cell migration and proliferation The E-cadherin epithelial cell adhesion protein is a tumor suppressor that has an important role in tumor metastasis The loss of expression of E-Cadherin during the epithelial mesenchymal transition EMT is often thought to promote metastasis by allowing the dissociation and invasion of cancer cells
The aim of this study is
1 To evaluate accuracy of SOX17 expression in neoplastic and hyperplastic endometrial lesions
2 To correlate SOX17 expression with some clinical and pathological parameters of endometrial carcinoma
3 To evaluate E-Cadhrin expression and its relation to SOX17 in neoplastic and hyperplastic lesions
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None